Silence Therapeutics
22 hedge funds and large institutions have $247M invested in Silence Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and closing their positions.
214% more funds holding
Funds holding: 7 → 22 (+15)
28.02% more ownership
Funds ownership: 6.53% → 34.55% (+28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (USA)
New York
|
+$66.5M |
| 2 |
Frazier Management
Seattle,
Washington
|
+$20.5M |
| 3 |
Goldman Sachs
New York
|
+$17.6M |
| 4 |
Axa
Paris,
France
|
+$15.3M |
| 5 |
Consonance Capital Management
New York
|
+$13.4M |
Top Sellers
SLN Hedge Fund Activity: Q4 2021 in Review
22 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2021, worth a combined $247M — up 527% from $39.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SLN positions and 0 closed out — a net gain of 15 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Lombard Odier Asset Management (USA), adding an estimated $66.5M.
- 22 institutional investors held Silence Therapeutics (SLN) as of Q4 2021, up from 7 in Q3 2021.
- Funds reported $247M of Silence Therapeutics stock for Q4 2021, up 527% quarter-over-quarter.
- 15 funds opened new Silence Therapeutics positions in Q4 2021 and 0 closed out, a net change of +15 holders.
- The largest Silence Therapeutics buyer in Q4 2021 was Lombard Odier Asset Management (USA), an estimated $66.5M added.
Based on aggregated 13F filings for Q4 2021.